You are here: Industry Insights > Market News > North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Tegoprazan

PFS filling & stoppering machine

Trimethyl Phloroglucinol

Digonal Sealing Labeling Machine

Round Bottle Labeling Machine

Capsule Checkweigher for Pharma Automatic Tablet Weighing Inspection Systems

North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

biospaceDecember 25, 2017

Tag: Insys , bribe

Favorites

North Carolina sued Insys on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic.

The lawsuit announced by North Carolina Attorney General Josh Stein comes amid a federal investigation that has led to charges against several former executives accused of engaging in a scheme to bribe doctors to prescribe Subsys.

Previous:Janssen Forges Global Pact With Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy

Next:FDA approves Ortho’s HIV diagnostic test

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

PharmaSourcesJuly 04, 2025

InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

ACN NewswireJune 20, 2025

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

PR NewswireJune 25, 2025

North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray | Pharmasources.com

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

ACN NewswireJune 23, 2025

Hua Medicine announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA).

亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may like
More>>

亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may likeMore>>

You may like
More>>